Wilmington Savings Fund Society FSB Decreases Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Wilmington Savings Fund Society FSB lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,914 shares of the company’s stock after selling 64 shares during the period. Wilmington Savings Fund Society FSB’s holdings in IDEXX Laboratories were worth $791,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in IDXX. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at $31,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter worth about $37,000. Institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $464.91 on Tuesday. The company has a market capitalization of $38.07 billion, a price-to-earnings ratio of 43.57, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company’s 50-day moving average is $428.35 and its 200 day moving average is $453.32.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on IDXX shares. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Finally, Barclays increased their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.